Related Experiment Video
Updated: Jun 8, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
Published on: January 12, 2024
Diabetes, glycemic control and risk of medical glaucoma treatment: A population-based case-control study
Lotte G Welinder1, Anders H Riis, Lars L Knudsen
1Department of Ophthalmology.
Purpose:
To examine the association between diabetes and risk of medical glaucoma treatment and to assess the role of long-term glycemic control in the putative association.
Design:
Population-based case-control study.
Methods:
Cases of treated glaucoma were all persons filling at least three prescriptions for glaucoma medication for the first time within one year between 2001 and 2006 in Northern Jutland, Denmark. We used risk set sampling to select 10 gender- and age-matched general population controls per case using the Danish Civil Registration System. Data on diabetes, comorbidities, and laboratory tests, including glycosylated hemoglobin (as a measure of glycemic control) were obtained from population-based medical registries. We calculated odds ratio (OR) as an estimate of relative risk for treated glaucoma comparing patients with and without diabetes, adjusted for comorbid conditions and medication use.
Results:
We included 5,991 persons with incident medical glaucoma treatment and 59,910 population controls. The adjusted OR for treated glaucoma for patients with diabetes was 1.81 (95% confidence interval: 1.65-1.98). The strength of the association between diabetes and glaucoma risk did not vary by diabetes duration or by the level of glycemic control.
Conclusions:
Regardless of glycemic control, diabetes is associated with a substantially increased risk for medical glaucoma treatment.
Related Concept Videos
Diabetic Retinopathy
Diabetes Mellitus: Type 2 and Gestational
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Hyperglycemia
Diabetes: Symptoms, Diagnosis, and Complications
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

